Senhwa Signs Agreement with Taiwan’s CDE for COVID-19 Program Guiding Development of Silmitasertib

Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and coronaviruses, today announced that its novel oral drug, …
( read original story …)

---